Global Hyperuricemia Drugs Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Hyperuricemia Drugs market size was valued at US$ 2705 million in 2024 and is forecast to a readjusted size of USD 5618 million by 2031 with a CAGR of 11.1% during review period.

Hyperuricemia is the type of condition wherein an excessive level of uric acid is produced in the blood. The level of uric acid in the blood is the balance between the breakdown of purines and the rate of uric acid excretion. The alteration in the uric acid level may cause hyperuricemia. High uric acid can result in serious diseases such as painful arthritis called gout.

Globally, the number of patients with hyperuricemia and gout is increasing year by year. According to statistics, the number of patients with hyperuricemia and gout in the world will reach 930 million in 2020, and the number of patients with hyperuricemia and gout in the world will be in 1.03 billion people in 2022.

This report is a detailed and comprehensive analysis for global Hyperuricemia Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Hyperuricemia Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Hyperuricemia Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Hyperuricemia Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Hyperuricemia Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Hyperuricemia Drugs

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Hyperuricemia Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Horizon Therapeutics plc, Takeda Pharmaceutical Company Ltd, Mylan NV, Novartis International AG, Regeneron Pharmaceuticals, Romeg Therapeutics, Teijin Pharma Ltd, Lannett Company, Inc, GSK Plc, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Hyperuricemia Drugs market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

NSAIDs

Xanthine Oxidase Inhibitor

Selective Uric Acid Reabsorption Inhibitor

Carbonic Anhydrase Inhibitor

Glucocorticoid

Other

Market segment by Application

Gout

Renal Calculus

Other

Major players covered

Horizon Therapeutics plc

Takeda Pharmaceutical Company Ltd

Mylan NV

Novartis International AG

Regeneron Pharmaceuticals

Romeg Therapeutics

Teijin Pharma Ltd

Lannett Company, Inc

GSK Plc

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Hyperuricemia Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Hyperuricemia Drugs, with price, sales quantity, revenue, and global market share of Hyperuricemia Drugs from 2020 to 2025.

Chapter 3, the Hyperuricemia Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Hyperuricemia Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Hyperuricemia Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Hyperuricemia Drugs.

Chapter 14 and 15, to describe Hyperuricemia Drugs sales channel, distributors, customers, research findings and conclusion.